Cargando…

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

SIMPLE SUMMARY: ctDNA assay is a promising non-invasive method to detect genomic alterations associated with lung cancer. In this prospective study of 25 patients with EGFR-mutant lung adenocarcinoma receiving osimertinib, ctDNA progression predated radiographic progression by 118 days in 11 of 20 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Chul, Xi, Liqiang, Cultraro, Constance M., Wei, Fang, Jones, Gregory, Cheng, Jordan, Shafiei, Ahmad, Pham, Trinh Hoc-Tran, Roper, Nitin, Akoth, Elizabeth, Ghafoor, Azam, Misra, Vikram, Monkash, Nina, Strom, Charles, Tu, Michael, Liao, Wei, Chia, David, Morris, Clive, Steinberg, Seth M., Bagheri, Hadi, Wong, David T. W., Raffeld, Mark, Guha, Udayan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268167/ https://www.ncbi.nlm.nih.gov/pubmed/34283064 http://dx.doi.org/10.3390/cancers13133342

Ejemplares similares

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports
por: Li, Ning, et al.
Publicado: (2020)

Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance
por: Maity, Tapan K., et al.
Publicado: (2023)

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021)

SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma
por: Venugopalan, Abhilash, et al.
Publicado: (2021)

Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021)

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
por: Venugopalan, Abhilash, et al.
Publicado: (2016)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors
por: Roper, Nitin, et al.
Publicado: (2019)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review
por: Wake, Laura, et al.
Publicado: (2019)

An UPLC-MS/MS Method for Determination of Osimertinib in Rat Plasma: Application to Investigating the Effect of Ginsenoside Rg3 on the Pharmacokinetics of Osimertinib
por: Ying, Zhenzhen, et al.
Publicado: (2020)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Saliva Secretion and Efficacy of Helicobacter Pylori Eradication in Peptic Ulcer Patients
por: Vahedi, M., et al.
Publicado: (2011)

PCR detection of Plasmodium falciparum in human urine and saliva samples
por: Mharakurwa, Sungano, et al.
Publicado: (2006)

Saliva testing
por: Croser, David
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Mutations in the JAK/STAT and RAS signaling pathways are common in Intestinal T-cell Lymphomas
por: Nicolae, Alina, et al.
Publicado: (2016)

Finding chinks in the osimertinib resistance armor
por: Leal, Jose Luis, et al.
Publicado: (2020)

The impact of medical cannabis consumption on the oral flora and saliva
por: Habib, George, et al.
Publicado: (2021)

Saliva Liquid Biopsy for Point-of-Care Applications
por: Aro, Katri, et al.
Publicado: (2017)

Sealing effectiveness of fissure sealant bonded with universal adhesive systems on saliva-contaminated and noncontaminated enamel
por: Memarpour, Mahtab, et al.
Publicado: (2018)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
por: Abdayem, Pamela, et al.
Publicado: (2020)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Osimertinib-associated ashy dermatosis–like hyperpigmentation
por: Lertpichitkul, Pattamon, et al.
Publicado: (2020)

1766. Osimertinib-Associated Progressive Multifocal Leucoencephalopathy
por: Gilotra, Tarvinder S, et al.
Publicado: (2019)

OSIMERTINIB PNEUMONITIS MASQUERADING AS COVID-19 PNEUMONIA
por: ALHALABI, ELIANE, et al.
Publicado: (2021)

Successful Management of Osimertinib-Induced Heart Failure
por: Fukuo, Atsuko, et al.
Publicado: (2022)

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
por: Ríos-Hoyo, Alejandro, et al.
Publicado: (2022)

Cardiac Safety of Osimertinib: A Review of Data
por: Ewer, Michael S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dse0rmvcv461bkbjmo8gm7vb2p